首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1547371

全球白介素抑制剂市场研究报告 - 2024 年至 2032 年行业分析、规模、份额、成长、趋势和预测

Global Interleukin Inhibitors Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 128 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球白血球介素抑制剂市场需求预计将从2023年的595亿美元达到2032年近2,631亿美元的市场规模，2024-2032年研究期间复合年增长率为17.96%。

白细胞介素抑制剂是指能够抑制白血球介素作用的免疫抑制剂。白细胞介素是一组由白血球合成的细胞激素。它们在免疫系统调节中发挥着至关重要的作用。白细胞介素抑制剂用于治疗各种自体免疫疾病和发炎性疾病。白细胞介素抑制剂的作用是靶向细胞因子，这些细胞因子在白血球之间充当化学讯号，对抗入侵感染的反应。它们抑制这些细胞因子的活性，从而减少发炎并抑制免疫系统。

市场动态

自体免疫疾病盛行率的上升和白血球介素抑制剂的日益普及是推动白血球介素抑制剂市场的主要因素。由于安全性和有效性的提高、专利到期以及肿瘤坏死因子(TNF) 生物仿製药越来越多地采用催产素药物的增加使用，人们对标靶治疗的偏好日益增加，从而导致了较高的市场需求。不断增加的新产品推出是重要的成长动力之一；例如，2019年，艾伯维公司推出了用于治疗斑块型干癣的Skyrizi（risankizumab-rzaa），刺激了预测期内的高市场需求。此外，上市产品的标籤扩展，例如治疗幼年特发性关节炎的Actemra 和治疗异位性皮肤炎的dupixent 以及有利的政府倡议，以及消费者意识的提高，可能会在未来几年为白细胞介素抑制剂市场的主要参与者创造利润丰厚的成长机会。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球白血球介素抑制剂市场的每个细分市场进行了包容性评估。白细胞介素抑制剂产业的成长和趋势为本研究提供了整体方法。

市场区隔

白细胞介素抑制剂市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按申请

牛皮癣
银屑病关节炎
类风湿关节炎
气喘
发炎性肠道疾病（IBD）
其他的

按类型

白细胞介素17
白细胞介素23
白细胞介素1
白细胞介素5
白细胞介素6
其他的

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲白细胞介素抑制剂市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。白血球介素抑制剂市场的主要参与者包括强生服务公司、诺华公司、艾伯维公司、礼来公司、再生元製药公司、阿斯特捷利康、鲍什健康、罗氏有限公司、葛兰素史克公司、梯瓦製药工业有限公司。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 8 章：白血球介素抑制剂公司的竞争格局

白血球介素抑制剂市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 9 章：公司简介

顶级公司市占率分析
市场集中度
Johnson & Johnson Services Inc.

公司概况
公司收入
产品
最新动态

Novartis AG

公司概况
公司收入
产品
最新动态

AbbVie Inc.

公司概况
公司收入
产品
最新动态

Eli Lilly And Company

公司概况
公司收入
产品
最新动态

Regeneron Pharmaceuticals Inc.

公司概况
公司收入
产品
最新动态

AstraZeneca

公司概况
公司收入
产品
最新动态

Bausch Health

公司概况
公司收入
产品
最新动态

F. Hoffmann-La Roche Ltd

公司概况
公司收入
产品
最新动态

GlaxoSmithKline Plc.

公司概况
公司收入
产品
最新动态

Teva Pharmaceuticals Industries Ltd

公司概况
公司收入
产品
最新动态

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR11215777

The global demand for Interleukin Inhibitors Market is presumed to reach the market size of nearly USD 263.1 Billion by 2032 from USD 59.5 Billion in 2023 with a CAGR of 17.96% under the study period 2024-2032.

Interleukin inhibitors refer to the immunosuppressive agents that can inhibit the interleukin's actions. Interleukins are a group of cytokines synthesized by white blood cells. They play a vital role in immune system regulation. Interleukin inhibitors are utilized to treat various autoimmune and inflammatory diseases. Interleukin inhibitors work by targeting cytokines that act as chemical signals between the white blood cells against the response of invading infection. They subdue the activity of these cytokines, thus reducing inflammation and suppressing the immune system.

MARKET DYNAMICS

The rising prevalence of autoimmune diseases and increasing adoption of interleukin inhibitors is the major factor driving the interleukin inhibitors market. The growing preference for targeted therapies is increasing due to their improved safety and efficacy profiles, patent expiry, and increased adoption of a biosimilar in Tumor Necrosis Factor (TNF) into the augmented usage of oxytocic drugs, which leads to high market demand. The rising new product launches are one of the important growth rendering drivers; for instance, in 2019, AbbVie, Inc. had launched Skyrizi (risankizumab-rzaa) for the treatment of plaque psoriasis treatment is stimulating the high market demand in the forecast period. Moreover, label expansions of marketed products, such as actemra for juvenile idiopathic arthritis and dupixent for atopic dermatitis and favorable government initiatives, and increasing consumer awareness is likely to create lucrative growth opportunities for key players of the interleukin inhibitors market in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Interleukin Inhibitors. The growth and trends of Interleukin Inhibitors industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Interleukin Inhibitors market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

Psoriasis
Psoriatic Arthritis
Rheumatoid Arthritis
Asthma
Inflammatory Bowel Disease (IBD)
Others

By Type

IL-17
IL-23
IL-1
IL-5
IL-6
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Interleukin Inhibitors market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Interleukin Inhibitors market include Johnson & Johnson Services Inc., Novartis AG, AbbVie Inc., Eli Lilly And Company, Regeneron Pharmaceuticals Inc., AstraZeneca, Bausch Health, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc., Teva Pharmaceuticals Industries Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. INTERLEUKIN INHIBITORS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Application
- 3.7.2 Market Attractiveness Analysis By Type
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL INTERLEUKIN INHIBITORS MARKET ANALYSIS BY APPLICATION

5.1. Overview By Application
5.2. Historical and Forecast Data Analysis By Application
5.3. Psoriasis Historic and Forecast Sales By Regions
5.4. Psoriatic Arthritis Historic and Forecast Sales By Regions
5.5. Rheumatoid Arthritis Historic and Forecast Sales By Regions
5.6. Asthma Historic and Forecast Sales By Regions
5.7. Inflammatory Bowel Disease (IBD) Historic and Forecast Sales By Regions
5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL INTERLEUKIN INHIBITORS MARKET ANALYSIS BY TYPE

6.1. Overview By Type
6.2. Historical and Forecast Data Analysis By Type
6.3. IL-17 Historic and Forecast Sales By Regions
6.4. IL-23 Historic and Forecast Sales By Regions
6.5. IL-1 Historic and Forecast Sales By Regions
6.6. IL-5 Historic and Forecast Sales By Regions
6.7. IL-6 Historic and Forecast Sales By Regions
6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL INTERLEUKIN INHIBITORS MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE INTERLEUKIN INHIBITORS COMPANIES

8.1. Interleukin Inhibitors Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF INTERLEUKIN INHIBITORS INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Johnson & Johnson Services Inc.
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Novartis AG
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. AbbVie Inc.
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. Eli Lilly And Company
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. Regeneron Pharmaceuticals Inc.
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. AstraZeneca
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Bausch Health
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. F. Hoffmann-La Roche Ltd
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. GlaxoSmithKline Plc.
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. Teva Pharmaceuticals Industries Ltd
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments